McKesson Corp - Company Profile
Powered by 
All the sales intelligence you need on McKesson Corp in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how McKesson Corp fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with McKesson Corp.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
McKesson Corp (McKesson) is a diversified healthcare services company focused on advancing health outcomes for patients. The company operates in the distribution of pharmaceutical drugs, medical-surgical supplies, and offers technology solutions. McKesson's main activities include distributing branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs, as well as medical-surgical supplies and laboratory equipment. Notable brands associated with McKesson include Health Mart and McKesson ConnectSM. The company's products and services cater to pharmacies, hospitals, healthcare providers, and biopharma companies. The company markets its products under the brand names of McKesson ConnectSM, Central FillSM, and McKesson SynerGx. The company offers prescription technology solutions to retail pharmacies in Canada. It has operations in the US, Canada, and Norway. McKesson is headquartered in Irving, Texas, the US.
Headquarters
United States of America
Address
6555 State Highway 161, Irving, Texas, 75039
Website
www.mckesson.com
Telephone
1 972 4464800
No of Employees
43,000
Industry
Wholesale
Ticker Symbol & Exchange
MCK (NYSE)
Revenue (2025)
$403.4B
12.4%
(2025 vs 2024)
EPS
XYZ
Net Income (2025)
XYZ
44.5%
(2025 vs 2024)
Market Cap*
$102.7B
Net Profit Margin (2025)
XYZ
28.3%
(2025 vs 2024)
* As of and is in US$
McKesson Corp premium industry data and analytics
Products and Services
| Products | Services |
|---|---|
| Branded Drugs | Distribution |
| Generic Drugs | Logistics |
| Specialty Drugs | Distribution |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Contracts/Agreements | In August, the company entered into an agreement to acquire Precision Medicine Group LLC, a provider of clinical research and biopharma commercialization services. |
| 2026 | Stake Sale | In June, the company sold a 13% stake in its Medical-Surgical Solutions to funds managed by affiliates of Apollo. |
| 2026 | Plans/Strategy | In February, the company announced its plans to integrate Ocado’s warehouse technology to enhance its logistics and fulfillment operations. |
Competitor Comparison
| Key Parameters | McKesson Corp | Cencora Inc | Cardinal Health Inc | Abbott Laboratories | Stryker Corp |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Irving | Conshohocken | Dublin | Abbott Park | Portage |
| State/Province | Texas | Pennsylvania | Ohio | Illinois | Michigan |
| No. of Employees | 43,000 | 51,000 | 63,900 | 115,000 | 56,000 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Brian S. Tyler | Chairman; Chief Executive Officer | Executive Board | 2019 | 59 |
| Kenny Cheung | Chief Financial Officer; Executive Vice President | Senior Management | 2026 | - |
| Francisco Fraga | Chief Technology Officer; Chief Information Officer; Executive Vice President | Senior Management | 2023 | - |
| Michele Lau | Executive Vice President; Chief Legal Officer | Senior Management | 2024 | 50 |
| Nimesh Jhaveri | Executive Vice President; Chief Impact Officer | Senior Management | 2023 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer